Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cigna Group SEC filings document financial results, governance actions and material events for a global health company operating through Cigna Healthcare, Evernorth Health Services and related subsidiaries. Form 8-K reports cover results of operations and financial condition, Regulation FD outlook disclosures, board and committee changes, leadership succession matters and shareholder meeting results.
Proxy materials describe director elections, executive compensation, shareholder voting items, board composition and governance practices. The filing record also includes exhibits for earnings releases and Inline XBRL cover data, tying formal disclosures to the company’s pharmacy benefit services, specialty and care services, health benefits operations, compliance oversight and public-company capital structure.
Cigna Group (CI) reported that executive vice president and special advisor to the CEO Everett Neville sold 617 shares of common stock on September 3, 2026 in an open-market or private transaction at $284.05 per share, pursuant to a Rule 10b5-1 trading plan adopted on June 2, 2026. Following this sale, he directly holds 5,053 shares of Cigna Group common stock.
Cigna Group (CI) reports that President and Chief Executive Officer Brian C. Evanko received equity awards on September 1, 2026. He was granted 6,716 stock options with an exercise price of $281.1325 per share and a separate award of 3,113 restricted shares, both vesting in three equal annual installments beginning September 1, 2027. Following these grants, he holds 41,030 common shares directly, plus indirect holdings of 25,614 shares through a GRAT and 919.5791 shares through Cigna’s 401(k) Plan. No Rule 10b5-1 trading plan is reported.
Cigna Group (CI) has a planned sale of common stock reported under Rule 144 for the account of officer Neville Everett. The notice covers 617 shares of common stock that were acquired through restricted stock vesting from the issuer as compensation on March 1, 2026, with an intended sale date around September 3, 2026 and an indicated aggregate value of $175,258.85.
Cigna Group (CI) director George Kurian reported an acquisition of 108.6642 phantom stock units on August 31, 2026 under the company’s director Deferral Plan, increasing his directly held phantom stock balance to 2,041.8523 units. These units represent voluntary deferral of a portion of his cash retainer into a hypothetical stock fund and are economically equivalent to Cigna common shares but will be settled in cash.
Cigna Group (CI) reported that executive Bryan Holgerson received small additional awards of phantom stock units linked to Cigna common stock. On 2026-07-09, 2026-07-23, and 2026-08-06 he acquired 0.8873, 0.9458, and 0.9837 units, respectively, under the Executive Deferred Compensation Plan, which are economically equivalent to CI shares but will be settled in cash. He also reports indirect ownership of 735.9274 CI common shares held through The Cigna Group's 401(k) Plan.
Cigna Group (CI) executive Nicole S. Jones, EVP, Chief Administrative Officer and Chief Human Resources Officer, reported selling 2,677 shares of common stock on 2026-08-18 at $279.61 per share in an open-market transaction pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. After this sale, she directly holds 25,880 shares and indirectly holds 1,451.2364 shares through participation in The Cigna Group's 401(k) Plan.
Cigna Group (CI) insider Nicole S. Jones filed a Rule 144 notice covering planned sales of common stock. The filing lists a planned stock option exercise and potential sale of 2,677 shares of Cigna common stock on 08/18/2025, for cash, through Fidelity Brokerage Services LLC. It also reports that during the past three months, Jones sold 19,436 shares of Cigna common stock for aggregate proceeds of $5,369,583.72.
The Cigna Group executive Nicole S. Jones, EVP and Chief Administrative and Chief Human Resources Officer, exercised 15,346 employee stock options at $192.02 per share on August 4–5, 2026, receiving common stock.
She also sold 19,436 common shares at $276.27 per share on August 4, 2026. All trades were made under a Rule 10b5-1 trading plan adopted May 4, 2026. As of August 4, 2026, she reported 1,451.2364 shares held indirectly through The Cigna Group's 401(k) Plan.
CI has filed to sell common stock under Rule 144. The filing lists 19,436 shares of common stock to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $5,369,583.72. Shares outstanding are reported as 264,240,486.
The shares derive from prior restricted stock vesting events in 2015, 2016, 2024, 2025 and 2026, and stock option exercises in 2019 and 2026, received as compensation or for cash.
The Cigna Group reported Q2 2026 results with total revenues of $71,668 million, up from $67,178 million a year earlier, driven mainly by higher Evernorth Health Services pharmacy revenues. Shareholders' net income was $1,660 million, and diluted EPS was $6.29, both above Q2 2025.
For the first half of 2026, revenues reached $140,162 million and shareholders' net income $3,314 million. As of June 30, 2026, the company reported $157,082 million in total assets and $42,620 million of shareholders' equity, including $6,298 million of cash and cash equivalents.
Net cash provided by operating activities was $710 million for the first six months, while the company repaid $550 million of maturing senior notes, maintained a $6,500 million undrawn revolving credit facility, and had $1,000 million of commercial paper outstanding. Cigna incurred $450 million of year-to-date strategic optimization program costs and continued returning capital through dividends and common share repurchases.